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Abstract
Viral infections are common causes of respiratory tract disease in
the outpatient setting but much less common in the intensive care
unit. However, a finite number of viral agents cause respiratory
tract disease in the intensive care unit. Some viruses, such as
influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV),
and varicella-zoster virus (VZV), are relatively common. Others,
such as adenovirus, severe acute respiratory syndrome (SARS)-
coronavirus, Hantavirus, and the viral hemorrhagic fevers (VHFs),
are rare but have an immense public health impact. Recognizing
these viral etiologies becomes paramount in treatment, infection
control, and public health measures. Therefore, a basic
understanding of the pathogenesis of viral entry, replication, and
host response is important for clinical diagnosis and initiating
therapeutic options. This review discusses the basic patho-
physiology leading to clinical presentations in a few common and
rare, but important, viruses found in the intensive care unit: influ-
enza, RSV, SARS, VZV, adenovirus, CMV, VHF, and Hantavirus.
Introduction
Viral infections are common causes for upper and lower
respiratory tract infections and a frequent reason for
outpatient office visits. Comparatively, viral respiratory infec-
tions are less common in the intensive care unit (ICU) setting
but still play an important clinical role. Most viral respiratory
infections in the ICU are community-associated cases with
severe lower respiratory disease that can progress into
respiratory failure and acute respiratory distress syndrome
(ARDS) [1]. The remainder are infections seen in immuno-
compromised patients, such as transplantation [2,3]. In some
instances (severe acute respiratory syndrome [SARS], influ-
enza, and adenovirus), viral respiratory infections present with
fulminant respiratory failure and ARDS, heralding a larger
community outbreak [4]. In these situations, the newly recog-
nized illness in an ICU patient might be the first presentation
of a larger public health emergency.
The clinical presentation, treatment, outcome, and personal
and institutional infection control differ greatly among the
most common viral infections in the ICU. These differences
are largely based on the viral structure, mode of transmission
and cell entry, and host immunology and thus provide the
foundation for the clinical presentation, virulence, and medical
therapeutics of these viral infections. Therefore, a basic
knowledge of the more common ICU viral respiratory patho-
gens will provide a framework for the clinical and research
approaches for these infections. This review will focus on the
basic epidemiology, virology, and host immune response for a
few common or high-impact viral respiratory pathogens in the
ICU: influenza, respiratory syncitial virus (RSV), SARS,
varicella-zoster virus (VZV), adenovirus, cytomegalovirus
(CMV), and viral hemorrhagic fever (VHF) (Table 1). With this
basic foundation, clinical care, public health, and medical
therapeutics for these viruses will be enhanced from the
laboratory to the bedside.
Influenza
Influenza causes a clinically recognizable, systemic illness
characterized by abrupt-onset fever, headache, myalgia, and
malaise (the classic influenza-like illness) [5]. Influenza is
subdivided into three distinct types: A, B, and C [5,6].
Influenza A infects a variety of species, including birds, swine,
horses, marine mammals, and humans [5,6]. Influenza B
infects only humans and predominates in children, and both
influenza A and B cause yearly outbreaks. Respiratory symp-
toms are usually self-limited. However, a small number of
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individuals can develop primary pneumonia, which can
progress to ARDS [5]. The respiratory symptoms will persist
or progress, and in a minority of cases ARDS can develop
[5,7-9]. The combination of pneumonia and ARDS usually
occurs in at-risk individuals, like individuals with chronic lung
diseases, but has been described in healthy individuals as
well. 
The structure of influenza’s viral envelope is important in viral
infection and thus host cell immunity [10,11]. The envelope
contains surface glycoproteins essential for virus entry into
the host cell. The trimeric hemagglutinin (HA) structure
undergoes limited proteolysis by host cellular proteases such
as furin. HA then binds to specific sialosaccharides found on
the surface of respiratory epithelial cells to initiate cell entry
[12]. The neuraminidase (NA) is an enzyme that catalyzes the
removal of terminal sialic acids from glycoproteins [12]. This
helps degrade respiratory tract mucus and release viral
progeny after cell infection and thus is necessary for
subsequent viral entry to viral escape from the host cell [12].
Influenza A is divided into subtypes based on H and N
antigenicity [11]. All H subtypes have been found in multiple
avian species and other animals. H1, H2, and H3 pre-
dominate in human disease seasonally, and more recently,
avian subtypes such as H5 and H7 have increased in humans
over the past decade [13-15]. 
Infection occurs when viruses containing aerosols are
deposited into the upper respiratory tract epithelium [5]. In
experimental volunteers, inoculation with small-particle aero-
sols more closely mimics natural disease than large drops
into the nose, illustrating the easy transmission with coughing
or sneezing [16,17]. The virus can attach (HA) and penetrate
the columnar epithelial cells. Predominantly human subtypes
(H1, H2, and H3) bind to alpha-2,6-galactose sialic acid
found in ciliated human respiratory tract epithelium [18]. On
the other hand, avian influenza subtypes (for example, H5N1)
bind preferentially to alpha-2,3-galactose sialic acid, which is
found in the gastrointestinal tract of water fowl, epithelial cells
on human conjunctivae, and on human type 2 pneumocytes
[18-20]. This preferential binding for specific sialic acid
receptors illustrates the differences in clinical presentation
seen with avian influenza infections in humans: conjunctivitis,
diarrhea, and fulminant alveolar pneumonia [20]. Additionally,
it underlies the difficulty with human-to-human transmission of
avian strains as preferential binding to type 2 pneumocytes
requires smaller particle aerosolization and deep inhalation
into the alveoli rather than larger droplets seen with seasonal
influenza transmission [20]. 
Host immunity occurs via a number of mechanisms. Upon
receptor binding, a large cytokine response occurs, with
interleukin (IL)-2, IL-6, and interferon gamma predominately
Table 1
Clinical and immunologic characteristics of major viruses found in the intensive care unit
Influenza RSV SARS-CoV VZV Adenovirus CMV VHF
Virus family Orthomyxo- Paramyxo- Coronaviridae Herpesvirdae Adenoviridae Herpesviridae Filoviridae
virdae virdae
Epidemiologic  Seasonal  Seasonal  Laboratory  Contact with  Military camps,  Transplantation,  Endemic area or 
link epidemic epidemic,  exposure on  infected  mental health  immuno- contact with 
immuno- known individual facilities suppressive  infected  individual
compromised infected  medications
and transplant individual
Pulmonary Primary  Upper  Rapid  Primary  Alveolar  Interstitial  Alveolar  edema
clinical alveolar  respiratory  tract  progressive  alveolar  pneumonia  pneumonitis, 
findings pneumonia infection, pneumonia,  pneumonia with  bronchiolitis bronchiolitis
bronchiolitis, ARDS
pneumonia
Lipid envelope Yes Yes Yes Yes No Yes Yes
Major receptor  Sialic acid RSV  CD209L  Glycoprotein  Coksackie- Unknown,  Folate receptor 
for cell entry glycoprotein G ACE 2 C and D adenovirus  involves  alpha
receptor integrens
Primary cell  Type 1  Type 1  Type 1  Macrophage  Type 1  Multiple Macrophages and 
of infection respiratory  respiratory  respiratory  and dendritic  respiratory  dendritic cells
epithelium epithelium epithelium cells epithelium
Viremia No No Yes Yes Yes Yes Yes
Primary host  Humoral Humoral Unknown Cellular Cellular  Cellular Humoral
immunity
ARDS, acute respiratory distress syndrome; CMV, cytomegalovirus; RSV, respiratory syncytial virus; SARS-CoV, severe acute respiratory
syndrome-coronavirus; VHF, viral hemorrhagic fever; VZV, varicella-zoster virus.Page 3 of 9
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[21]. This leads to extensive local inflammation with neutro-
phils and macrophages infiltrating the subepithelium of the
respiratory tract. In cases of severe avian subtypes, a hemo-
phagocytic syndrome and severe diffuse alveolar damage
occur, causing the clinical findings of severe pneumonia and
respiratory failure [21]. Within the alveolar macrophages and
pneumocytes, major histocompatibility complex (MHC) I up-
regulation leads to antigen presentation of the HA and other
subcapsular proteins [22,23]. This eventually leads to natural
killer cell destruction of infected cells and the development of
neutralizing antibodies (largely against HA) by day 14 of
infection [22].
Treatment of active influenza involves antiviral agents and
supportive care. The most effective therapy is prevention via
vaccination and infection control [4,5,13]. Two types of anti-
viral medications have been used: (a) M2 inhibitors (amanta-
dine and rimantadine) inhibit the M2 ion channel needed for
viral replication [24]. These are not active against influenza B
and C and resistance is common in seasonal influenza. Thus,
they should be used only in cases of known susceptibility. (b)
The NA inhibitors, oseltamivir and zanamivir, have less
resistance and prevent cleavage of sialic acid, which is
necessary for a new virus to exit from the host cell [24].
Studies with the NA inhibitors show a reduction in symptom
time and viral shedding, with peak effect when started within
48 hours of symptom onset [4,5,13]. However, treatment with
NA inhibitors after 48 hours may provide some additional
benefit but has not been fully studied [13]. Resistance is low
within the community, but NA inhibitor resistance has already
been described in clinical isolates from human cases of avian
influenza.
Respiratory syncytial virus
Respiratory syncytial virus (RSV) is the most common cause
of lower respiratory tract infections in children under 1 year of
age, and healthy adults are infected repeatedly throughout
their lives [25,26]. Adults typically have upper respiratory
tract symptoms; however, some adults will develop lower
respiratory tract infections, including bronchiolitis, pneu-
monia, and (rarely) ARDS [25-28]. The elderly and immuno-
compromised, particularly bone marrow transplant patients,
are at highest risk of lower respiratory tract infection and
respiratory failure [28]. In these cases, upper airway infection
usually precedes lower tract infection by 1 to 3 days.
Infection follows a pattern similar to influenza, with epidemics
occurring in the winter months [25].
Inoculation occurs at the nasal or ocular mucosa via direct
contact with secretions or infected fomites [29,30]. RSV has
a lipoprotein envelope with surface glycoproteins that are
important in host infection [31,32]. These glycoproteins act
as cell fusion proteins, ultimately forming multinucleated giant
cells (‘syncytia’), assisting in cell-to-cell spread [31,32]. The
virus replicates locally and then spreads to the epithelium of
the bronchioles. From the bronchioles, the virus can then
extend to the type 1 and 2 alveolar pneumocytes [31,33].
Infection leads to cellular (neutrophils, monocytes, and
T cells) infiltration of the epithelium and supplying vascula-
ture, with subsequent necrosis and proliferation [31,33]. This
will cause the airway obstruction, air trapping, and increased
airway resistance that are characteristic of RSV infection
[25,31,33]. RSV infection is more specifically associated with
IL-6 and macrophage inflammatory protein-1 (MIP-1) release
[34-36]. Elevated levels of IL-6 and MIP-1 in the bronchioles
have correlated with more severe disease [37]. 
Both droplet and contact transmissions are the main methods
of spread, and thus hand washing, droplet isolation, and the
use of personal protective equipment are all important in
reducing viral spread [29,30]. Specific genotypes will pre-
dominate during a seasonal outbreak, and since the geno-
types change annually, adult reinfections occur [32]. Treat-
ment usually is focused on controlling bronchospasm and
preventing spread to other patients and health care workers
[25,28]. Bronchodilators and corticosteroids are used for
bronchospasm, and aerosolized ribivirin has been used in
severe and high-risk cases such as bone marrow transplants
[25,28]. However, a recent study evaluating bronchiolitis in
infants, in which over 50% of cases were caused by RSV,
showed that corticosteroids had no effect on outcome [38].
Severe acute respiratory distress syndrome
SARS is caused by a novel coronavirus (SARS-CoV) that
was first detected in 2003 [39,40]. The initial outbreak
rapidly spread into a global epidemic, with cases reported
from 29 countries. The fatality rate was 11%, with most
deaths in patients older than 65 and no deaths in children
[39-41]. Since the initial epidemic in 2003, no new cases
have been reported. SARS appears to clinically present as a
two-stage illness. The initial prodrome, characterized by fever
with or without rigors, malaise, headache, and myalgias,
occurs an average of 7 days after contact with infected
individuals [40-42]. Some patients also have mild respiratory
symptoms or nausea and diarrhea. The respiratory phase
appears to develop approximately 8 days after the onset of
fever [40-42]. Forty-five percent of patients will develop
hypoxemia and approximately 20% of these patients will
progress to acute lung injury and require mechanical
ventilation [40-42]. SARS-CoV appears to have originated
from the horseshoe bat. The horseshoe bat appeared to be a
natural reservoir for the virus and the civet cat acted as an
intermediate host, allowing transmission to humans [43,44].
Like RSV and influenza, SARS-CoV has a lipoprotein
envelope, but unlike the RSV and influenza, the virus is
assembled and obtains its envelope from the endoplasmic
reticulum [45]. SARS-CoV, like other coronaviruses, starts
with infection of the upper respiratory tract mucosa [40].
SARS-CoV binds to CD209L (L-SIGN) and ACE-2, two
functional receptors on the respiratory tract epithelium
[46,47]. After binding, local inflammation and edema increase.
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reducing alveolar fluid, and thus the binding of SARS-CoV to
ACE-2 may contribute to the dysregulation of fluid balance in
the alveolar space [48]. Additionally, low mannose-binding
lectin (MBL) levels are thought to play a role in SARS
pathogenesis [49]. In many respiratory infections, MBL
prevents receptor attachment, activates complement, and
enhances phagocytosis. In SARS-CoV infections, low or
deficient levels of MBL have been noted, particularly asso-
ciated with an MBL haplotype [49]. The binding of SARS-
CoV to ACE-2, along with lower levels of MBL, leads to
higher viral levels, increased alveolar edema, and the severe
acute respiratory failure associated with SARS-CoV. 
Viral spread is by droplet transmission, although many cases
suggest that airborne and contact routes also occur [39].
Spread to health care workers who wore appropriate
personal protective equipment suggests an airborne mode,
and additional spread by aerosol-generating procedures,
such as resuscitation (cardiopulmonary resuscitation), medi-
cation nebulization, and noninvasive ventilation, further
supports this mode [39,50-52]. The treatment for SARS is
largely supportive with low tidal volume mechanical ventilation
[40,53]. Numerous treatment strategies, including
corticosteroids, ribavirin, immunoglobulin, and interferon,
have been investigated in SARS: none has been
demonstrated to provide clinical evidence of benefit.
Varicella-zoster virus
VZV infection routinely occurs during childhood, presenting
with low-grade fever, malaise, pharyngitis, and a vesicular
rash [54,55]. Primary disease occurs throughout the year and
usually is self-limited in immunocompetent host. VZV pneu-
monia is rare in children. However, it is the most frequent
complication in adults (20%) and accounts for the majority of
hospitalizations from VZV [56,57]. Varicella pneumonia
develops insidiously, usually a few days after the onset of
rash, and can progress to respiratory failure and ARDS
[56,57]. Risk factors for VZV pneumonia and ARDS include
pregnancy, smoking, and immunosuppression (malignancy,
corticosteroids, HIV, and solid-organ transplant), but young
healthy adults rarely develop ARDS [54,58]. Mortality for VZV
pneumonia is 10% to 30%, with a mortality of 50% when
respiratory failure ensues [54,58]. Additional complications
include encephalitis, hepatitis, and secondary skin and soft
tissue infections.
VZV is a herpes virus, a common group of DNA viruses that
have a lipid-containing envelope with surface glycoproteins
[59]. Infection starts in the upper respiratory tract mucosa as
the surface glycoprotiens allow for fusion of the lipid
envelope with the respiratory cell membrane [60,61]. Upon
cell entry, viral replication and assembly occur after
integration of the viral genes into the cellular DNA [60,61].
Naked capsids then acquire their envelope at the nuclear
membrane and are released into the perinuclear space where
large vacuoles are formed, leading to the clinical vesicles
[60,61]. Local replication and spread lead to seeding of the
reticuloendothelial system and ultimately viremia, which leads
to diffuse and scattered skin lesions associated with primary
varicella [62,63]. Viral shedding can last from onset of fever
until all lesions have crusted and pneumonia has improved.
Both humoral immunity and cell-mediated immunity are
involved in protection [62,64]. Antibodies are directed at the
surface glycoprotein and lead to viral neutralization. Cellular
immunity drives local inflammation, leading to cell repair and
vacuole removal. The virus becomes latent within the dorsal
root ganglia [59,63]. During latency, the viral DNA is located
in the cytoplasm rather than integrated into nuclear DNA.
VZV is highly contagious and transmission is via respiratory
droplets and direct contact with lesions [56,62]. The
envelope is sensitive to detergent and air drying, which
account for the lability of VZV on fomites. In adults who
progress to pneumonia or ARDS, treatment with acyclovir
and corticosteroids has been shown to lessen hospital and
ICU stays [62,65,66]. In immunocompromised persons not
previously exposed to VZV, varicella-zoster immune globulin
has been shown to be useful for both prevention of disease
and symptomatic improvement [62,65,66].
Adenovirus
Adenovirus is the one of the most common causes of upper
respiratory tract infections in adults and children [67,68].
Clinical disease usually is a self-limited upper respiratory tract
infection associated with conjunctivitis; however, severe
lower respiratory disease can occur in both high-risk and
healthy individuals [67,69-71]. The combination of pneu-
monia and ARDS develops in a minority of individuals and
usually is associated with conjunctivitis and other extra-
pulmonary manifestations, such as gastrointestinal disease,
hepatitis, meningitis, and hemorrhagic cystitis [68]. The
extrapulmonary complications, along with ARDS, are more
frequent in transplant recipients. Pneumonia and ARDS
appear to be more common with subtype E type 4 and
subgroups B type 7, but serogroup 35 also has been
documented in mental health facilities [69-71]. Recent
increases in respiratory diseases in adults have been noted
over the past year with serotype 14 [72].
Over 51 human adenovirus subtypes exist and clinical syn-
dromes vary among subtypes [53]. However, certain sub-
types appear to have an increased likelihood of lower
respiratory tract involvement and this appears to be related to
the viral capsid proteins [73]. Unlike influenza, RSV, and
SARS, adenovirus is a DNA virus covered by a protein capsid
without a lipid envelope. Rodlike structures called fibers are
one of three capsid protein types (hexons, pentons, and
fibers) and these fibers are the attachment apparatus for viral
adsorption to the cell [73]. Attachment occurs at the cox-
sackieadenovirus receptor, the same receptor as the
coxsackie B virus. The hexon capsid protein appears to have
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adenoviruses and contains other sites that show type
specificity [73]. Fiber antigen seems to be primarily type-
specific with some group specificity, whereas the penton
base antigen is common to the adenovirus family. Upon
infection, respiratory epithelial cells express these capsid
proteins on their surface, leading to direct CD8+ cytotoxic
T-cell MHC class 1 killing of these cells [74]. Thus, epithelial
destruction associated with submucosal edema drives the
clinical findings of lower respiratory disease [67]. Additionally,
neutralizing antibody is directed at the hexon type-specific
antigen and provides some future protection against
serotypes [74].
Adenovirus is relatively stable on environmental surfaces for
long periods of time, and thus viral spread is largely
associated with infected fomites [53,67]. Spread also occurs
via droplet transmission. Treatment is largely supportive. For
severe cases, especially in immunosuppressed patients,
antiviral therapy has been attempted but no clinical studies
exist [69-72]. In severe cases, especially in immuno-
compromised patients, ribavirin and cidofovir antiviral therapy
has been attempted, but no controlled clinical trials exist.
Cytomegalovirus
CMV is a common viral infection that causes both primary
and latent infections. Seroprevalence rates range from 60%
to 70% in US adult populations [75,76]. CMV causes a wide
spectrum of illness, ranging from an asymptomatic infection
to a mononucleosis syndrome, organ-specific complications,
and fulminant multisystem disease [77-79]. Immuno-
competent patients are more likely to present with minimal to
no symptoms, whereas immunocompromised patients are
more likely to develop organ-specific complications and
fulminant disease [77-79]. The most significant and severe
disease syndromes are found in lung, liver, kidney, and heart
transplant recipients [80]. Significant morbidity and mortality
usually are confined to immunocompromised persons;
however, previously healthy individuals can present with
organ-specific complications or even present with fulminant
disease [78,80]. 
CMV is a member of the herpes virus family and, like other
members of this family, is known for causing latent infections
[75]. Like other herpes viruses, CMV is an enveloped virus
with multiple surface glycoproteins. These glycoproteins are
important for viral entry into host cells and are targets for host
cell humoral and cell-mediated immunity [75,81]. The cellular
protein that serves as the specific receptor for CMV entry has
not been identified, but CMV infects cells by a process of
endocytosis [37]. Once entry has occurred, CMV alters host
immunity through the activation of multiple genes. One
important CMV protein prevents cellular HLA-1 molecules
from reaching the cell surface, preventing recognition and
destruction by CD8+ T lymphocytes [82]. Thus, the CMV
genome can remain in infected cells and avoid immune
destruction, which accounts for its latency in clinical disease.
Eventually, a cellular immune response, driven by high levels
of anti-CMV CD4+ and CD8+ T cells, leads to control of the
disease [37,82,83]. Antibodies against CMV do not provide
significant immunity [83]. 
Avoiding immune detection gives CMV the ability to remain
latent after infection, which contributes a great deal to serious
CMV disease. Evidence for persistent CMV genomes and
antigens exists in many tissues after initial infection, and CMV
has been found in circulating mononuclear cells and in
polymorphonuclear neutrophils [84]. The virus can be
cultured from most bodily fluids, including blood, urine, stool,
tears, semen, and breast milk, and from mucosal surfaces,
including the throat and cervix [85-88]. Detection of cells that
contain CMV intranuclear inclusions in renal epithelial tissue
and in pulmonary secretions provides evidence that CMV
may persist in these tissues as well. CMV antigens have also
been detected in vascular endothelial cells; this site has been
suggested as a cause of vascular inflammation and
development of atherosclerosis [89]. When immune
suppression occurs in patients by means of HIV infection or
through immunosuppressive therapy, such as antilymphocyte
antibody infusion, CMV can reactivate, producing end-organ
disease [80,83]. Specifically from a pulmonary standpoint,
CMV is common after lung transplantation, causing an acute
pneumonitis or contributing to a chronic bronchiolitis [90]. In
HIV patients, CMV pneumonitis is rare but postmortem
studies suggest that pulmonary disease from CMV occurs at
higher rates than previously recognized [90].
CMV is transmitted via many routes. Transmission has been
observed among family members (thought to be secondary to
close contact and viral shed from the upper respiratory tract),
among children and employees at daycare centers, from
sexual contact, blood and tissue exposure (seroconversion
after transfusion of blood products or organ transplantation),
and perinatally (during birth or from breast milk) [85-88].
There are several antiviral agents available for systemic
treatment of CMV. These agents include ganciclovir,
valgancicilovir, foscarnet, and cidofovir [9,37,91].
Viral hemorrhagic fevers
The VHFs include a wide number of geographically
distributed viruses found worldwide, including Ebola and
Marburg viruses, Rift Valley fever, Crimean Congo hemor-
rhagic fever, Lassa fever, yellow fever, and dengue fever.
Ebola and Marburg viruses are in the family filoviridae
[92-95]. Although the underlying pathophysiology differs
slightly between the VHFs, Marburg and Ebola viruses serve
as a classic template [92-95].
Marburg virus has a single species whereas Ebola has four
different species that vary in virulence in humans [92-95]. The
clinical manifestations of both Marburg and Ebola viruses are
similar in presentation, with a higher mortality with Ebola Zaire
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only major difference between them. The initial incubation
period after exposure to the virus is 5 to 7 days, with clinical
disease beginning with the onset of fever, chills, malaise,
severe headache, nausea, vomiting, diarrhea, and abdominal
pain [92-94,96]. With this initial infection, macrophages and
dendritic cells initially are the site of viral replication, followed
by spread to the reticuloendothelial system heralding the
initial onset of symptoms [97]. As macrophages and other
infected tissues undergo necrosis, an overwhelming cytokine
response occurs, leading to abrupt prostration, stupor, and
hypotension [92,93,96,98]. Particularly, tumor necrosis factor
(TNF), IL-1, IL-6, macrophage chemotactic protein, and nitric
oxide levels are markedly increased [98]. VHF-infected macro-
phages, along with noninfected macrophages stimulated by
cytokines, release cell surface tissue factor, which subse-
quently triggers the extrinsic coagulation pathway [97,98].
The clinical and laboratory findings of impaired coagulation
with increased conjunctival and soft tissue bleeding shortly
follow [95,98]. In some cases, more massive hemorrhage can
occur in the gastrointestinal and urinary tracts, and in rare
instances, alveolar hemorrhage can occur [95,96,98,99]. The
onset of maculopapular rash on the arms and trunk also
appears to be classic and may be a very distinctive sign.
Along with the bleeding and hypotension, multiorgan failure
occurs, eventually leading to death [95,96,98,99]. The over-
whelming viremia resulting in macrophage and dendritic cell
apoptosis leads to impaired humoral immunity, which in turn
leads to increase viral production [98]. This ultimately results
in the rapid overwhelming shock seen with VHFs.
Transmission appears to occur through contact with
nonhuman primates and infected individuals [95]. No specific
therapy is available and patient management includes suppor-
tive care [92,93,95,98]. In a few cases in the Zaire outbreak
of Ebola in 1995, whole blood with IgG antibodies against
Ebola may have improved outcome, although subsequent
analysis suggests that these patients were likely to survive
even without this treatment [100].
Hantavirus
Hantavirus is one of four major genera within the family
bunyaviridae, a family of more than 200 animal viruses spread
via arthropod-vertebrate cycles [101-103]. Hantavirus causes
two severe acute febrile illnesses: hemorrhagic fever with renal
syndrome (HFRS) (found in the Old World) and Hantavirus
cardiopulmonary syndrome (HPS) (found in the New World)
[101-103]. HPS was first classified in the Southwestern US. A
new species termed Sin Nombre virus was identified after an
outbreak in the Four Corners region of the Southwestern US in
1993 [101-103]. In North America, disease largely has been
reported in the Southwest and California, with cases reported
in Canada, Europe, China, Chile, Argentina, and other parts of
South America. Outbreaks are often cyclical and focal and are
affected by weather and climatic variables and the effect this
has on rodent populations [104]. 
Symptoms begin with a prodrome of fever, chills, and
myalgias; HFRS and HPS also can be accompanied by
abdominal pain and gastrointestinal disturbances [101-104].
In HPS, initially, there is an absence of upper respiratory
symptoms. At about day 5, modest dry cough and dyspnea
will develop. Due to the severe increase in vascular perme-
ability associated with HPS, disease progresses rapidly
(within hours) to respiratory failure, shock, ARDS, coagulo-
pathy, and arrhythmias [104,105]. Resolution also can occur
rapidly. If hypoxia is managed and shock is not fatal, the
vascular leak reverses in a few days and recovery is
apparently complete. Notably, thrombocytopenia with an
immunoblast-predominant leukocytosis is characteristic of the
early cardiopulmonary phase [104,105].
The exact mechanism for ARDS, shock, and coagulopathy is
unclear, but it is suspected that the immune response, rather
than the virus itself, causes the capillary leak and shock. The
intense cellular immune response alters endothelial cell
barrier function and is harmful. Hantavirus causes an
increased release of TNF and alpha interferon and increased
MHC I antigen presentation [106,107]. There is also a more
intense CD8+ T-cell response in sicker patients [106,107]. It
appears to result from a massive acute capillary leak
syndrome and shock-inducing mechanisms thought to be due
to the release of kinins and cytokines [106,107]. The
syndrome’s clinical presentation, rapid resolution, and histo-
pathologic findings of interstitial infiltrates of T lymphocytes
and alveolar pulmonary edema without marked necrosis
support this underlying process. Treatment mainly is
supportive, with extracorporeal membrane oxygenation being
used in some cases [104,105]. Ribavirin has been effective
in HFRS, but not HPS. Mortality remains at roughly 20%.
Conclusion
Viral infections in the ICU are common in the outpatient
setting but become less common in the ICU. However, a
small number of viral infections can lower respiratory tract
disease and subsequent respiratory failure. These viral
pathogens vary greatly in clinical disease, from rapid and
fulminant respiratory failure and shock (VHF) to chronic latent
disease of immunosuppression (CMV). However, most of
these viruses commonly have lipid envelopes, except for
adenovirus, and all have surface proteins or glycoprotiens
that allow for attachment, cell entry, and virulence. Host
response to these infections varies from primarily cellular to
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This article is part of a review series on 
Infection, 
edited by Steven Opal.
Other articles in the series can be found online at
http://ccforum.com/articles/
theme-series.asp?series=CC_Infectionhumoral. All can cause respiratory disease but a few are of
great public health concern, particularly novel strains of
influenza, adenovirus, SARS, and VHFs. An understanding of
the basic viral pathogenesis, along with host response, allows
for a foundation in treatment and public health response
within the ICU.
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